Company background

BiosparQ’s technology was initially developed by Delft University of Technology and leading Dutch research institute TNO for an aerosol early warning system for bio-agent attacks commissioned by the Dutch Ministry of Defense.

In 2012, BiosparQ acquired all assets and IP from TNO to continue the development of the technology for medical and industrial markets.

In addition, BiosparQ matured the aerosol platform, which led to an application engineering contract with Thales Communications & Systems, Q-Linea and TNO commissioned by the European Defense Agency.

BiosparQ Team

  • Gerold de Valk, CEO

MSc Applied Physics (TU Delft), various TNO business development, project- and line management positions, TNO contracts officer.

  • René Parchen, CTO

PhD Applied Physics (TU Eindhoven), TNO senior research scientist / system engineer

  • Herman Vos

MSc Mechanical Engineering (TU Delft), CFO of 3 high tech ventures, investment banking at ABN AMRO

Company history

In June 2009, under the umbrella of TNO Companies BV, Gerold de Valk founded BiosparQ BV. Founding this company was a logical step to take the BiosparQ technology to the next level. Bringing the activities in a private setting provided significant allotments of time to help define the business, link it with resources, recruit additional talent and raise capital.

In 2012, after a management buyout and two seed rounds, an A financing round was closed with an informal investor who helped the company to mature further. The company moved from Delft to the Leiden Bio Science Park, where the BiosparQ laboratory infrastructure and offices reside since then.

In 2013, the European Defense Agency took over the role of the Dutch MoD regarding bio-detector development and procurement. BiosparQ BV is now part of the consortium together with Thales Communications & Security, Q-Linea and TNO.

References

Prof. dr. Paul Savelkoul
Professor Savelkoul (1960) is head of the department Medical Microbiology at the MUMC+ (Maastricht, NL). He is also a professor medical microbiology at the MUMC+ and the Amsterdam VU Medical Center .

His research focuses on molecular diagnostics, detection and typing of pathogenic micro-organisms and molecular epidemiology. He is also active in the field of identification of risk factors that contribute to the spreading of bacterial infections and the identification and characterization of multi-resistant bacteria, that create a serious threat for treatment of patients in hospitals all over the world.

Professor Savelkoul is member of several professional societies. He is the chairman of the European Study Group on Molecular Diagnostics (ESGMD) and he is also the chairman of the section microbial typing of the Royal Dutch Society for Microbiologists. He is the author of more than 120 peer reviewed scientific articles.

Professor Savelkoul is one of the founders of the education for molecular medical microbiologist, he is the organizer for several post-academic courses and he is also a teaching professor for the registration for molecular medical microbiologist.
T: +3120 4440552/488 (secr)
E: p.savelkoul@vumc.nl

Dr. Bas Zaat
S.A.J. Zaat is one of the Amsterdam Academic Medical Center Principal Investigators. Focus of his research: Biomaterial-associated infections and novel antimicrobial strategies.

Biomaterial-associated infections, i.e. infections of biomedical devices, or “biomaterials” (catheters, prosthetic heart valves, implants), are a major and increasing problem in modern medicine, especially in view of the increase in antibiotic resistance. Bacterial, biomaterial, and host-responses involved in the pathogenesis are subject of studies, in order to find novel approaches for treatment and prevention. In the NANTICO (Non-adherent ANTImicrobial Coatings) consortium project different antimicrobial coating strategies have been developed to prevent infection. In the IBIZA (Imaging of Biomaterial-associated Infection using a novel model for testing new biomaterials is being developed, and in the BALI (Biofilm Alliance) EU FP7 project we develop novel Synthetic Antimicrobial Antibiofilm Peptides for controlled release coatings to prevent infection of titanium implants.

He and Dr. Andrej Trampuz from the Berlin Charité are the driving forces behind a research project where the Biosparq platform is used to treat patients with prosthetic joint infections (PJIs) more effectively.
T: +3120 5664863
E: s.a.zaat@amc.uva.nl

Dr. Yves Gaubert
Dr. Yves Gaubert is head of the CBRN (Chemical Biological, Radiological and Nuclear defense) department at Thales Communications & Security (Fr).  His business line designs, delivers and integrates high-technology solutions to protect critical infrastructures for local authorities and corporate and government customers worldwide against CBRN attacks. The company’s comprehensive services offering ranges from security consulting, architecture definition and complex systems integration to complete turnkey solutions for security systems.

Dr. Yves Gaubert is familiar with BiosparQ and acted as bid manager during the proposal phase of the European Defense Agenency project IPODS. In this project, the BiosparQ sensor is integrated together  with an immuno based sensor into one single platform to provide military users with an early warning system against attacks with bio-agentia.
T: +33 1 73 32 21 67
M: +33 6 71 92 17 52
E: yves.gaubert@thalesgroup.com

Dr. Stéphane Morel
Dr. Stéphane Morel is de Thales projectmanager for the EDA project IPODS.
T: +33 (0)1 73 32 21 45
M: +33 (0)6 87 77 96 59
E: stephane.morel@thalesgroup.com

Prof. dr. Jan Verhoef
Professor Verhoef (1944) received his M.D. and Ph.D. in Microbiology at the University of Utrecht where he has been Professor of Clinical Microbiology. From 1978 till 2008 Prof. Verhoef has been Chairman of the Eijkman-Winkler Institute of Medical and Clinical Microbiology at the University of Utrecht. From 1983 to 1990 he was a member of the Dutch Governmental Advisory Board for the Registration of Drugs. He was the founder of Ugene B.V. (CRO) which was later sold to Kendle International. He received several honours and awards and has been a member of advisory boards of many pharmaceutical and biotechnology companies. He was the founder and first president of the European Society of Clinical Microbiology & Infectious Diseases.  Prof. Verhoef is also a member of the editorial board at several journals. He published over 650 scientific publications in journals and books.

Professor Verhoef is an advisor to BiosparQ.
M: +31 625050770
E: jan.verhoef@planet.nl